

ANALYSIS OF TREATMENT RESOLUTIONS OF BIOLOGICAL THERAPY BY A LOCAL DERMATOLOGY COMMITTEE IN A THIRD LEVEL HOSPITAL

M.I. SIERRA TORRES¹, A. RODRIGUEZ PEREZ¹, M.D. TOSCANO GUZMAN¹, E. MONTECATINE ALONSO, C. VILLANUEVA BUENO¹, L.L. POYATOS RUIZ¹, M.D. SANTOS RUBIO¹, A. LLUCH COLOMER¹, M. SORIANO MARTINEZ¹, A. GARCIA-AVELLO FERNANDEZ-CUETO¹.
¹HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO, PHARMACY, SEVILLE, Spain.

BACKGROUND

The high cost of biological treatment justifies the need for supervision and monitoring of patients by the requesting department (Dermatology) and the service responsible for dispensing (Pharmacy)


PURPOSE

To analyse the verdicts on requests for biological treatment, issued by a committee of dermatologists.

MATERIAL AND METHOD

- Descriptive, retrospective study. Topical applications allowed by a local committee were reviewed between September 2013 and March 2014.
- The variables collected were: diagnosis, suggested treatment, verdict, therapeutic alternative in case of refusal, Psoriasis Area Severity Index (PASI) (>10 as initial criterion) and % body surface area (BSA) affected at the beginning.
- Treatment adherence was also checked, using the prescriptions dispensed by the pharmacy.


RESULTS



34 approved treatments:

- 25 patients BASI > 10
- 3 patients < 10
- 7 patients unknown

88% patients are still collecting their medication



Alternatives treatments:

- No treatment (1)
- Ciclosporine (4)
- Metotrexate (2)
- Phptotherapy (2)

CONCLUSIONS

- Expert advice can help to regulate the use of biological therapies, restricting them to patients for whom there is solid evidence to support its use, and offering a therapeutic alternative in case of refusal.
- The Pharmacy Service reviews patient progress and adherence to treatment, thus promoting rational drug use.